Related Experiment Videos

Gentamicin inactivation in purulent exudates: role of cell lysis

Insights

Gentamicin is inactivated by binding to DNA released from lysed polymorphonuclear leukocytes (PMNLs) in purulent exudates. This binding explains how the antibiotic loses effectiveness in infection sites.

Area of Science:

  • Microbiology
  • Pharmacology
  • Cell Biology

Background:

  • Gentamicin is an aminoglycoside antibiotic crucial for treating bacterial infections.
  • Purulent exudates, common in infections, can reduce gentamicin's efficacy.
  • The precise mechanisms of gentamicin inactivation in exudates are not fully understood.

Purpose of the Study:

  • To investigate the factors responsible for gentamicin binding and inactivation by purulent exudates.
  • To elucidate the role of human polymorphonuclear leukocytes (PMNLs) in this process.
  • To identify the specific components within PMNLs that bind gentamicin.

Main Methods:

  • Utilized an in vitro model with purified human PMNLs.
  • Compared gentamicin binding to intact versus freeze-thawed (lysed) PMNLs.
  • Assessed the effect of DNase I, RNase, Triton X-100, and protease on binding.
  • Investigated binding using purified PMNL chromatin and DNA.

Main Results:

  • Intact PMNLs showed minimal gentamicin binding, while lysed PMNLs exhibited extensive binding.
  • Gentamicin binding correlated with the concentration of lysed PMNLs and antibiotic added.
  • Binding was highly sensitive to DNase I, indicating DNA's role, but unaffected by RNase, Triton X-100, or protease.
  • Purified DNA and chromatin from PMNLs replicated the binding pattern.

Conclusions:

  • Gentamicin inactivation in purulent exudates is linked to its binding by lysed PMNLs.
  • PMNL chromatin DNA is a primary factor responsible for gentamicin binding and subsequent inactivation.
  • Understanding this interaction is key to improving antibiotic efficacy in infections.

Related Concept Videos